Dolan Christine
Known title: See RemarksCIK: 0001684273
Associated companies
Transaction History
| MRVI | ▲ Buy | Grant | 5,006 | $9K | 5/15/2026 | View on chart |
| MRVI | ▼ Sell | Tax Withholding | 28,661 | $88K | 3/16/2026 | View on chart |
| MRVI | ▼ Sell | Tax Withholding | 28,934 | $107K | 1/15/2026 | View on chart |
| MRVI | ▲ Buy | Grant | 4,300 | $8K | 11/14/2025 | View on chart |
| MRVI | ▲ Buy | Grant | 2,381 | $4K | 5/15/2025 | View on chart |
| MRVI | ▼ Sell | Tax Withholding | 5,336 | $14K | 3/17/2025 | View on chart |
| MRVI | ▲ Buy | Grant | 246,549 | — | 3/17/2025 | View on chart |
| MRVI | ▼ Sell | Tax Withholding | 1,621 | $7K | 2/18/2025 | View on chart |
| MRVI | ▼ Sell | Tax Withholding | 28,704 | $131K | 1/15/2025 | View on chart |
| MRVI | ▲ Buy | Grant | 1,848 | $11K | 10/31/2024 | View on chart |
| MRVI | ▲ Buy | Grant | 483 | $3K | 4/30/2024 | View on chart |
| MRVI | ▼ Sell | Tax Withholding | 5,383 | $41K | 3/15/2024 | View on chart |
| MRVI | ▼ Sell | Tax Withholding | 1,941 | $11K | 2/15/2024 | View on chart |
| MRVI | ▲ Buy | Grant | 189,604 | — | 1/16/2024 | View on chart |
| MRVI | ▲ Buy | Grant | 1,729 | $10K | 10/31/2023 | View on chart |
| MRVI | ▲ Buy | Grant | 1,394 | $16K | 4/28/2023 | View on chart |
| MRVI | ▲ Buy | Grant | 55,775 | — | 3/15/2023 | View on chart |
| MRVI | ▼ Sell | Tax Withholding | 1,956 | $30K | 2/15/2023 | View on chart |
| MRVI | ▲ Buy | Grant | 666 | $15K | 4/29/2022 | View on chart |
| MRVI | ▲ Buy | Grant | 17,000 | — | 1/25/2022 | View on chart |
| MRVI | ▲ Buy | Grant | 203 | $5K | 10/31/2021 | View on chart |
| MRVI | ▲ Buy | Grant | 916 | $21K | 4/30/2021 | View on chart |
AI Market Commentary
AI-generatedAll commentary →Synthesized from recent news and fundamentals/technical data -- not human analyst commentary or trader sentiment.
October 13, 2026
Maravai LifeSciences Releases Q2 2026 Earnings Call Transcript
Maravai LifeSciences has published the full transcript of its second-quarter 2026 earnings call. This document provides detailed management commentary on recent operational performance and financial results. The release serves as a primary source for investors seeking to understand the company's current strategic direction and outlook.
Maravai LifeSciences Releases Q2 2026 Earnings Call Transcript. Maravai LifeSciences has published the full transcript of its second-quarter 2026 earnings call. This document provides detailed management commentary on recent operational performance and financial results. The release serves as a primary source for investors seeking to understand the company's current strategic direction and outlook.